A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections

Inclusion Criteria: * 18-85 years old, male or female. * Patients who are admitted to ICU wards. * Patients clinically diagnosed with carbapenem-resistant organism (CRO) infections, and has been commenced on targeted therapy with ceftazidime-avibactam. * One or more organ dysfunction criteria in the previous 24 hours i. MAP \< 60 mmHg for at least 1 hour; ii. Vasopressors required for \> 4 hours; iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour. iv. Serum creatinine concentration \> 220 μmol/L or \>2.49 mg/dL Exclusion Criteria: * Patient has a known allergy to ceftazidime-avibactam. * Patient has received ceftazidime-avibactam for more than 48 hours during current infectious episode. * Patient is in severe condition or expected to survive for no more than 48 hours. * Patient who receives lung or heart transplant or stem cell transplant. * Patient is known or suspected to be pregnant. * Patient has previously been enrolled in the current study. * Other conditions which are regarded as inappropriate for enrollment.